IL-1-conferred gene expression pattern in ERα
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Survival
Estrogen Receptor alpha
/ metabolism
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Interleukin-1
/ pharmacology
Male
Prostatic Neoplasms
/ drug therapy
Receptors, Androgen
/ metabolism
SOX9 Transcription Factor
/ genetics
Sequestosome-1 Protein
/ genetics
Signal Transduction
Transcriptional Activation
Androgen receptor
Breast cancer
Estrogen receptor
Interleukin-1
Prostate cancer
p62/SQSTM1
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Jan 2020
20 Jan 2020
Historique:
received:
05
09
2019
accepted:
10
01
2020
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
22
9
2020
Statut:
epublish
Résumé
Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resistance. We have previously reported that interleukin-1 (IL-1) inflammatory cytokine downregulates ERα and AR mRNA in HR-positive (HR We performed RNA sequencing (RNA-seq) for HR We identified 350 genes in common between BCa and PCa cells that are induced or repressed by IL-1 in HR Our 350 gene set can be used to identify novel therapeutic targets and/or biomarkers conserved among acquired (e.g. due to inflammation) or intrinsic HR-independent BCa and PCa.
Sections du résumé
BACKGROUND
BACKGROUND
Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resistance. We have previously reported that interleukin-1 (IL-1) inflammatory cytokine downregulates ERα and AR mRNA in HR-positive (HR
METHODS
METHODS
We performed RNA sequencing (RNA-seq) for HR
RESULTS
RESULTS
We identified 350 genes in common between BCa and PCa cells that are induced or repressed by IL-1 in HR
CONCLUSIONS
CONCLUSIONS
Our 350 gene set can be used to identify novel therapeutic targets and/or biomarkers conserved among acquired (e.g. due to inflammation) or intrinsic HR-independent BCa and PCa.
Identifiants
pubmed: 31959131
doi: 10.1186/s12885-020-6529-9
pii: 10.1186/s12885-020-6529-9
pmc: PMC6971947
doi:
Substances chimiques
AR protein, human
0
Biomarkers, Tumor
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
Interleukin-1
0
Receptors, Androgen
0
SOX9 Transcription Factor
0
SOX9 protein, human
0
SQSTM1 protein, human
0
Sequestosome-1 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001105
Pays : United States
Organisme : NCI NIH HHS
ID : R21CA175798
Pays : United States
Organisme : NCI NIH HHS
ID : K01CA160602
Pays : United States
Organisme : NIH HHS
ID : UL1TR001105
Pays : United States
Références
Int J Oncol. 1999 Nov;15(5):1033-7
pubmed: 10536189
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20567-74
pubmed: 19074260
Nat Commun. 2016 Jan 12;7:10318
pubmed: 26754771
Am J Clin Exp Urol. 2013 Dec 25;1(1):53-65
pubmed: 25374900
Development. 2003 Dec;130(23):5681-93
pubmed: 14522876
Semin Cancer Biol. 2015 Dec;35:133-44
pubmed: 26299608
Oncotarget. 2018 Jan 10;9(7):7604-7615
pubmed: 29484136
Autophagy. 2011 Mar;7(3):341-5
pubmed: 21079414
Redox Biol. 2018 Jul;17:246-258
pubmed: 29729523
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):148-156
pubmed: 28344099
Prostate Suppl. 1998;8:32-6
pubmed: 9690661
Oncogene. 2003 Apr 17;22(15):2322-33
pubmed: 12700667
BMC Cancer. 2011 Apr 12;11:130
pubmed: 21486440
Carcinogenesis. 2017 Oct 26;38(11):1092-1103
pubmed: 28968743
Cancer Res. 2013 Jun 1;73(11):3297-305
pubmed: 23536554
J Biol Chem. 2010 May 28;285(22):16782-8
pubmed: 20378532
Cancer Res. 2008 Mar 15;68(6):1625-30
pubmed: 18339840
J Cell Biochem. 2014 Dec;115(12):2188-97
pubmed: 25103771
J Biol Chem. 2010 Jan 15;285(3):2077-89
pubmed: 19903815
Int J Gynecol Cancer. 2006;16 Suppl 2:556-9
pubmed: 17010072
Nat Rev Urol. 2017 Nov;14(11):683-696
pubmed: 28895566
Nat Cell Biol. 2010 Mar;12(3):213-23
pubmed: 20173742
Ther Adv Med Oncol. 2012 Jul;4(4):195-210
pubmed: 22754593
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6502-7
pubmed: 15096597
J Oncol. 2019 Apr 1;2019:6754040
pubmed: 31057614
Biomed Pharmacother. 2018 Dec;108:766-773
pubmed: 30248545
J Transl Med. 2006 Nov 10;4:48
pubmed: 17096856
J Immunol. 1994 Jul 15;153(2):712-23
pubmed: 8021507
J Cancer. 2018 Oct 18;9(21):4072-4086
pubmed: 30410612
Mol Cell. 2016 Sep 15;63(6):976-89
pubmed: 27594448
J Cell Biol. 2011 Jan 10;192(1):17-27
pubmed: 21220506
Oncogene. 2017 Jan 19;36(3):304-317
pubmed: 27345399
Cell. 2009 Jun 12;137(6):1001-4
pubmed: 19524504
Oncogene. 2019 Apr;38(17):3151-3169
pubmed: 30622340
J Interferon Cytokine Res. 2015 Jan;35(1):1-16
pubmed: 25068787
Onco Targets Ther. 2013 Jul 19;6:883-8
pubmed: 23888115
Int J Oncol. 2003 Aug;23(2):269-84
pubmed: 12851675
Prostate. 2018 Apr;78(5):390-400
pubmed: 29368435
Oncotarget. 2015 Apr 10;6(10):8167-84
pubmed: 25717032
Prostate. 2014 Feb;74(2):149-63
pubmed: 24122957
Nat Rev Urol. 2014 Apr;11(4):213-9
pubmed: 24535589
Genes Dis. 2014 Dec;1(2):149-161
pubmed: 25685828
Endocr Relat Cancer. 2015 Feb;22(1):R51-67
pubmed: 25404688
Biochem Biophys Res Commun. 2017 Aug 26;490(3):780-785
pubmed: 28645612
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Biol Chem. 2007 Apr 6;282(14):10553-60
pubmed: 17277314
Clin Cancer Res. 2016 Nov 15;22(22):5514-5526
pubmed: 27252418
J Biol Chem. 2007 Aug 17;282(33):24131-45
pubmed: 17580304
Stem Cell Res Ther. 2018 Sep 26;9(1):242
pubmed: 30257726
J Cell Biol. 2005 Nov 21;171(4):603-14
pubmed: 16286508
Breast Cancer Res. 2007;9(1):R15
pubmed: 17261184
Cancer Treat Rev. 2015 Dec;41(10):884-92
pubmed: 26342718
PLoS One. 2014 Dec 10;9(12):e114964
pubmed: 25494214
Endocr Rev. 1997 Feb;18(1):26-45
pubmed: 9034785
Biochem J. 2015 Aug 1;469(3):347-55
pubmed: 26205490
Oncotarget. 2016 Nov 15;7(46):75571-75584
pubmed: 27765923
Am J Cancer Res. 2012;2(4):397-413
pubmed: 22860231
J Biol Chem. 2005 Oct 21;280(42):35625-9
pubmed: 16079148
Cancer Res. 2007 Jan 15;67(2):528-36
pubmed: 17234760
J Biomed Sci. 2017 Dec 04;24(1):90
pubmed: 29202842
Int J Mol Sci. 2019 Aug 06;20(15):null
pubmed: 31390729
PLoS One. 2013;8(1):e53936
pubmed: 23349769
J Clin Invest. 2016 May 2;126(5):1745-58
pubmed: 27043282
J Biol Chem. 2010 Sep 3;285(36):27879-90
pubmed: 20573959
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
Cancer Res. 2003 Sep 15;63(18):5754-60
pubmed: 14522896
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Cancer Invest. 2000;18(4):293-302
pubmed: 10808364
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Cancer Res. 2010 Feb 1;70(3):979-87
pubmed: 20103652
Oncogenesis. 2017 Apr 3;6(4):e310
pubmed: 28368389
J Cell Biochem. 2018 Oct 15;:
pubmed: 30324661
Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034
pubmed: 20066092
Prostate Cancer. 2012;2012:128965
pubmed: 23326670
Endocr Relat Cancer. 2007 Mar;14(1):73-80
pubmed: 17395976
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Exp Ther Med. 2011 Sep;2(5):887-891
pubmed: 22977593
Prostate. 2004 Jan 1;58(1):82-94
pubmed: 14673956
Arch Med Res. 2010 Apr;41(3):170-81
pubmed: 20682174
Histopathology. 2006 Jan;48(2):157-61
pubmed: 16405664
Prostate. 2018 Jun;78(8):595-606
pubmed: 29527701
Clin Cancer Res. 2015 Aug 1;21(15):3471-9
pubmed: 25925890